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Abstract
Background: Managing blood pressure in patients with acute kidney injury (AKI) could effectively prevent severe-
stage progression. However, the effect of hypotension duration in the early phase of AKI remains poorly understood.
This study investigated the association between early-phase cumulative duration of hypotension below threshold
mean arterial pressure (MAP) and severe-stage progression of oliguric AKI in critically ill patients, and assessed the
difference in association with presence of sepsis.
Methods: This was a single-center, observational study conducted in the ICU of a university hospital in Japan. We
examined data from adults with oliguric AKI who were admitted to the ICU during 2010–2014 and stayed in the ICU
for ≥24 h after diagnosis of stage-1 oliguric AKI defined in the Kidney Disease Improving Global Outcomes (KDIGO)
guidelines. The primary outcome was the progression from stage-1 oliguric AKI to stage-3 oliguric AKI (progression to
oligoanuria and use of renal replacement therapy) according to the KDIGO criteria. During the first 6 h after oliguric AKI,
we analyzed the association between cumulative time the patient had below threshold MAP (65, 70, and 75 mm Hg)
and progression to stage-3.
Results: Among 538 patients with oliguric AKI, progression to stage-3 increased as the time spent below any threshold
MAP was elongated. In the multivariable analysis of all patients, longer hypotension time (3–6 h) showed significant
association with stage-3 progression for the time spent below MAP of 65 mm Hg (adjusted odds ratio (OR) 3.73, 95%
confidence interval (CI) 1.53–9.09, p = 0.004), but the association was attenuated for the threshold MAP of 70 mm Hg
(adjusted OR 2.35, 95% CI 0.96–5.78, p = 0.063) and 75 mm Hg (adjusted OR 1.92, 95% CI 0.72–5.15, p = 0.200). Longer
hypotension time with the thresholds of 65 and 70 mm Hg was significantly associated with the risk of stage-3
progression in patients without sepsis, whereas the association was weak and not significant in patients with sepsis.
Conclusions: Even in a short time frame (6 h) after oliguric AKI diagnosis, early-phase cumulative hypotension duration
was associated with progression to stage-3 oliguric AKI, especially in patients without sepsis.
Keywords: Critical illness, Acute kidney injury, Arterial pressure, Hypotension, Intensive care unit, Epidemiology
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Background
Acute kidney injury (AKI) is an extremely common
burden in intensive care units (ICUs) [1]. When critical
illness is complicated by AKI, there is a well-known as-
sociation with increased mortality [1, 2], but preventive
measures have not yet been established. Maintenance
of normal or even increased mean arterial pressure
(MAP) could provide a benefit because autoregulation
of blood flow is known to be lost during certain forms
of AKI, especially in patients with sepsis [3]. Recent
studies [4, 5] suggest that maintaining MAP ≥70 mm
Hg could better protect patients with sepsis and AKI
compared to maintaining MAP ≥65 mm Hg as recom-
mended in the worldwide guidelines for sepsis [6, 7].
Other studies indicate that the time elapsed with blood
pressure below threshold might be the key indicator of
developing postoperative AKI [8, 9]. On the other hand,
the optimal blood pressure threshold is still a matter of
debate. Some studies have failed to indicate the effect-
iveness of maintaining high MAP in AKI management
[10, 11].
Blood pressure management strategies to prevent pro-
gression of AKI to severe stages need to be established.
Some reports exhibit the association between the time
spent with blood pressure below threshold MAP and
progression of AKI in patients with sepsis [12, 13]. How-
ever, whether intensivists should also manage blood
pressure in patients with AKI without sepsis remains a
point of contention [4, 5, 12–14]. Moreover, it is uncer-
tain whether managing hypotension duration in early-
phase AKI is important in preventing progression to
severe-stage AKI.
This study focused on oliguria, an easy-to-find
marker for early-stage AKI in the ICU. In the early
phase of oliguric AKI (6 h after the diagnosis of oliguric
AKI), we investigated the association between cumula-
tive hypotension duration below threshold MAP and
progression of AKI among critically ill patients with
and without sepsis.
Methods
Study design, setting, and patients
This observational study reviewed data from all con-
secutive patients admitted to the ICU of the Jikei
University School of Medicine, Tokyo, Japan, from
January 2010 through December 2014. The study
protocol was approved by the respective medical insti-
tutional review boards of Kyoto University (approval
number R0432) and Jikei University (approval number
27-299). Because of the retrospective approach of this
study and de-identification of personal data, the boards
waived the need for informed consent.
We examined data from consecutive patients aged
≥18 years who had not undergone maintenance dialysis
and who stayed in the ICU for at least 24 h after the
diagnosis of oliguric AKI, which was defined as stage-1
oliguric AKI, urine output <0.5 mL/kg/h for 6 h con-
secutively (Table 1), according to the Kidney Disease
Improving Global Outcomes (KDIGO) criteria [15]. If
patients with oliguric AKI were admitted to the ICU
twice or more during the study period, only data from
the first ICU admission were included. We excluded
patients in whom blood pressure was not measured
with an interval of <1 h during the 24-h period after
oliguric AKI diagnosis, and those who died within 72 h
after ICU admission. Patients who had been admitted
after vascular surgery were excluded because they were
frequently treated with higher target levels of blood
pressure in the ICU to avoid spinal ischemia and para-
plegia [16]. We also excluded patients in whom renal
replacement therapy (RRT) was initiated within 6 h of
oliguric AKI diagnosis.
Data collection
Data for analyses including age, sex, body weight, co-
morbidities, ward type before ICU admission, surgery
type for postoperative patients, prevalence of sepsis at
ICU admission, length of ICU stay, ICU mortality, and
hospital mortality were collected from the ICU data-
base. In this study, sepsis was defined as the presence
of known active systemic infection at ICU admission,
the presence of shock at ICU admission caused by sus-
pected infection, or positive blood culture sampled at
ICU admission. We also collected data on urine output
for 7 days after ICU admission or until ICU discharge,
blood pressure, and intravenous administration of vaso-
active agents (dopamine, dobutamine, norepinephrine,
and vasopressin) for 6 h after oliguric AKI diagnosis via
the electronic medical record system (PIMS; Philips Japan
Table 1 Staging of acute kidney injury for adults according to
KDIGO
Staging Serum creatinine Urine output
Stage 1 1.5–1.9 times baseline, or ≥0.3 mg/
dL (≥26.5 μmol/L) increase
<0.5 mL/kg/h for 6–12 ha
Stage 2 2.0–2.9 times baseline <0.5 mL/kg/h for ≥12 h
Stage 3 3.0 times baseline, or
increase in serum creatinine
to ≥4.0 mg/dL (≥353.6 μmol/L),
or initiation of renal replacement
therapy
<0.3 mL/kg/h for ≥24 hb,
or anuria for ≥12 hb
Acute kidney injury (AKI) is defined as any of the following: (1) increase in
serum creatinine by ≥0.3 mg/dL (≥26.5 μmol/L) within 48 h; (2) increase in
serum creatinine by ≥1.5 times baseline, which is known or presumed to have
occurred within the prior 7 days; (3) urine output <0.5 mL/kg/h for 6 h. AKI
was diagnosed according to the Kidney Disease Improving Global Outcomes
(KDIGO). aDefinition of stage-1 oliguric AKI in this study. bDefinition of stage-3
oliguric AKI (progression to oligoanuria and use of renal replacement therapy)
in this study
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Ltd.). The time between ICU admission and oliguric AKI
diagnosis (time to oliguric AKI) was calculated.
Illness severity was assessed using Acute Physiology
and Chronic Health Evaluation (APACHE) II scores [17]
and Sequential Organ Failure Assessment (SOFA) scores
[18] during the first 24-h period after ICU admission. In
the ICU, urine output was recorded every 2 h. The MAP
was recorded every 15 minutes. We collected fluid bal-
ance data, but the time to obtain the fluid balance infor-
mation was predefined at three points per day (at 5:00,
13:00 and 21:00 h) in the ICU. Therefore, we obtained
fluid balance data during the first measurable 8-h period
after oliguria started. Although we also obtained serum
creatinine at ICU admission, we did not collect baseline
serum creatinine data because our prior research shows
that more than half of the patients in the ICU did not
have baseline creatinine recorded [19].
Outcome measures
The primary outcome measure was progression to stage-3
oliguric AKI (progression to oligoanuria and use of renal
replacement therapy (RRT)) according to the KDIGO
criteria: RRT initiation during the stay in the ICU, urine
volume <0.3 mL/kg/h for 24 h consecutively within 7 days
after ICU admission, or anuria for 12 h consecutively
within seven days after ICU admission (Table 1) [15]. We
did not use the criteria for serum creatinine in the KDIGO
guidelines, because we specifically examined oliguria as
the marker for early diagnosis of AKI. We additionally
performed sensitivity analyses by focusing on initiation of
RRT as the outcome.
Measure of main exposure factors
To assess the association between blood pressure and
the progression to stage-3 oliguric AKI, we considered
the cumulative hypotension duration as the most clinic-
ally relevant variable of blood pressure parameters
based on recent studies [8, 9]. Here, we set three
hypotension thresholds: MAP of 65, 70, and 75 mm
Hg. The cumulative time below a particular threshold
MAP in a 6-h period after oliguric AKI diagnosis was
considered as the main exposure factor for stage-3 pro-
gression. Stage-3 progression according to the urine
output criteria is possible at 6 h after the oliguric AKI
diagnosis. Therefore, we stopped data collection on expos-
ure at 6 h after oliguric AKI diagnosis. We also calculated
the “time-averaged MAP,” “lowest MAP” and “area under
threshold MAP” in the 6-h period.
Statistical analysis
Data were analyzed as medians with interquartile range
(IQR) for continuous variables and as proportions for
categorical variables, to which the Mann–Whitney U
test and Fisher's exact test or chi-squared test were
applied, respectively. We first visually described the
relationship between the cumulative time spent below
each threshold MAP (65, 70, and 75 mm Hg) and pro-
gression to stage-3 AKI using restricted cubic splines in
univariable logistic regression models. To evaluate the
predictability of each blood pressure parameter for stage-3
progression, we drew the area under the receiver operat-
ing curve (AUROC).
As the primary analysis, multivariable logistic regres-
sion models were used to assess the association be-
tween the time categories below each threshold MAP
and stage-3 progression. Here, the time category was
divided into none (0 hours), minimal through 3 h (0–3 h)
and 3 through 6 h (3–6 h), and the odds ratios (ORs) and
the 95% confidence intervals (CIs) were calculated. The
following variables were incorporated into the primary
multivariable models: serum creatinine levels at ICU ad-
mission, the prevalence of sepsis at ICU admission, and
APACHE II scores. Furthermore, we performed subgroup
analyses stratified by sepsis and non-sepsis to elucidate
the differences in etiology. All statistical analyses were
performed using R (The R Foundation for Statistical
Computing, ver. 3.30) and EZR (Saitama Medical
Center, Jichi Medical University, ver. 1.32), which is a
graphical user interface for R [20]. All tests were two-
tailed; p values <0.05 were regarded as statistically
significant.
Results
The selection process for the study patients is presented
in Fig. 1. We extracted 807 patients who stayed in the
ICU for ≥24 h after oliguric AKI diagnosis. After exclud-
ing 269 patients who met the aforementioned exclusion
criteria, we enrolled 538 patients with stage-1 oliguric
AKI for our analyses. Progression to stage 3 was ob-
served in 27 (19.6%) of 138 patients with sepsis and 27
(6.8%) of 400 patients without sepsis at ICU admission.
Patient characteristics, vasoactive use and fluid balance
are presented in Table 2. Among the patients, 51.7% (278/
538) were admitted to the ICU after surgery; 25.7% (138/
538) had sepsis at ICU admission. The median APACHE
II score was 17 (IQR 13–22). Patients with stage-3 pro-
gression had significantly higher serum creatinine levels at
ICU admission (1.54 mg/dL vs. 0.86 mg/dL, p < 0.001),
shorter time to oliguric AKI (10.7 h vs. 19.0 h, p = 0.001),
higher SOFA scores (11 vs. 7, p < 0.001), and higher
APACHE II scores (22 vs. 17, p < 0.001). During the 6-h
period after oliguric AKI diagnosis, patients with stage-
3 progression had more frequently received norepin-
ephrine (66.7% (36/54) vs. 42.4% (205/48), p = 0.001)
and vasopressin (11.1% (6/54) vs. 2.9% (14/484), p =
0.010) than patients without progression. During the
first measurable 8-h period after the start of oliguria,
patients with stage-3 progression had more fluid input
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(949 mL vs. 758 mL, p = 0.004), less fluid output (272 mL
vs. 326 mL, p = 0.028) and more positive fluid balance
(723 mL vs. 432 mL, p < 0.001) than in patients without
progression. In patients with sepsis, however, the fluid pa-
rameters were similar between groups of patients with
stage-3 progression and those with no progression (input:
848 mL vs. 840 mL, p = 0.265; output: 281 mL vs. 262 mL,
p = 0.979; balance: 514 mL vs. 470 mL, p = 0.551). Of all
patients, 6.7% (36/538) and 15.6% (84/538) died in the
ICU and in hospital, respectively.
Blood pressure parameters in patients with stage-3 pro-
gression and those with no progression are presented in
Table 3. Among all patients, patients with stage-3 progres-
sion exhibited significantly lower time-averaged MAP
(71 mm Hg vs. 75 mm Hg, p = 0.003), lower lowest MAP
(61 mm Hg vs. 65 mm Hg, p < 0.001), larger area under
any threshold MAP (65 mm Hg: 2.0 h × mm Hg vs.
0.0 h ×mm Hg, p = 0.001; 70 mm Hg: 10.0 h × mm Hg
vs. 3.3 h × mm Hg, p = 0.001; 75 mm Hg: 27.8 h × mm
Hg vs. 14.4 h × mm Hg, p = 0.001), and longer time
below any threshold MAP (65 mm Hg: 0.5 h vs. 0.0 h,
p = 0.002; 70 mm Hg: 2.4 h vs. 1.0 h, p = 0.002; 75 mm
Hg: 4.6 h vs. 2.8 h, p = 0.002) than patients without
progression. The AUROC of time-averaged MAP and
lowest MAP was 0.62 (95% CI 0.54–0.71) and 0.63
(95% CI 0.55–0.71), respectively, for all patients. The
AUROC of area under threshold MAP was 0.63 (95%
CI 0.55–0.71) in 65 mm Hg, 0.63 (95% CI 0.55–0.71) in
70 mm Hg and 0.64 (95% CI 0.56–0.71) in 75 mm Hg.
For the AUROC of time below threshold MAP, the
AUROC was 0.62 (95% CI 0.54–0.70) in 65 mm Hg,
0.63 (95% CI: 0.55–0.70) in 70 mm Hg and 0.63 (95%
CI: 0.55–0.71) in 75 mm Hg.
The longer the time below any threshold MAP
continued, the more frequently stage-3 progression oc-
curred (Fig. 2 and Table 4). Primary multivariable logis-
tic regression models revealed that a hypotension
duration of 3–6 h was significantly associated with
stage-3 progression when threshold MAP was 65 mm
Hg (adjusted OR 3.73, 95% CI 1.53–9.09, p = 0.004);
however, such an association was attenuated when the
threshold was 70 mm Hg (adjusted OR 2.35, 95% CI
0.96–5.78, p = 0.063) and 75 mm Hg (adjusted OR 1.92,
95% CI 0.72–5.15, p = 0.200) (Table 4). When the pa-
tients were stratified into patients with or without sep-
sis, the hypotension time of 3–6 h below MAP 65 and
70 mm Hg was significantly associated with stage-3
progression in patients without sepsis (65 mm Hg: ad-
justed OR 4.53, 95% CI 1.35–15.30, p = 0.015; 70 mm
Hg: adjusted OR 4.42, 95% CI 1.03–19.00, p = 0.046),
but was weak and not significant in patients with sepsis
(Table 4). The results were similar when we performed
sensitivity analyses by focusing on RRT initiation
(Table 5).
Discussion
In this study, we demonstrated that early-phase cumula-
tive hypotension time spent below a particular threshold
MAP was associated with progression to stage-3 oliguric
AKI (progression to oligoanuria and use of RRT) among
critically ill patients with early oliguric AKI, especially in
patients without sepsis. This is the first report examining
the level and duration of hypotension, and the septic
state in patients with early oliguric AKI, and may pro-
vide information to guide the management of early-stage
AKI in the ICU.
Fig. 1 Flow of patients with oliguric acute kidney injury (AKI) admitted to the ICU from January 2010 through December 2014. BP blood pressure,
RRT renal replacement therapy
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Which blood pressure parameter is the best - time-
averaged MAP, the area under threshold MAP, or time
below threshold MAP? From the calculated AUROC,
the prediction of stage-3 progression was similar. Previ-
ous researchers have reported the optimal threshold of
blood pressure to prevent AKI by examining time-
averaged MAP [4, 5]. However, in our study, although
the difference in time-averaged MAP in patients with
and without stage-3 progression was statistically signifi-
cant, we should consider whether the difference was
clinically meaningful (71 mm Hg vs. 75 mm Hg)
(Table 3). In addition, the method using time-averaged
MAP does not consider variation in blood pressure. Is
the method appropriate to investigate the optimal
threshold of blood pressure? On the other hand, in pa-
tients who underwent non-cardiac surgery, the time
spent below intraoperative MAP of 55–60 mm Hg has
been strongly associated with increased risk of postoper-
ative AKI [8, 9]. The primary outcome in these studies
was not progression to severe-stage AKI, and not all pa-
tients were admitted to the ICU. Although the outcome
and patient profile of these studies are different from
those of our study, they indicate the importance of
cumulative hypotension time in AKI research. Accord-
ingly, in our study, we examined both area under
threshold MAP and time below threshold MAP, consid-
ering the importance of hypotension time, and time
below threshold MAP seemed comparable with and
easier to apply in clinical practice than area under
threshold MAP (Table 3).
In this study, hypotension below a particular threshold
MAP was associated with stage-3 progression. Surviving
Sepsis Campaign Guidelines recommend maintaining
MAP ≥65 mm Hg in patients with sepsis [6, 7], while
some earlier reports indicate that maintenance of MAP
≥70 mm Hg would prevent AKI and progression to
severe-stage AKI. Badin and colleagues reported that
time-averaged MAP of 72–82 mm Hg might be neces-
sary for septic shock patients with AKI defined by serum
creatinine, to prevent progression of AKI [4]. On the
other hand, a recent large randomized controlled trial
comparing mortality, AKI incidence, and RRT initiation
between the target MAP of 65–70 mm Hg (low-target
Table 2 Patient characteristics, vasoactive use and fluid balance










69 (61–78) 70 (59–77) 0.647
Male (%) 41 (75.9) 335 (69.2) 0.351
Body weight (kg;
median (IQR))
62.0 (52.3–67.8) 60.0 (50.0–70.0) 0.571
Comorbidities (%)
Immunocompromised 8 (14.8) 42 (8.7) 0.141
Hematologic malignancy 2 (3.7) 12 (2.5) 0.642
Metastasis 0 (0.0) 14 (2.9) 0.380
Respiratory failure 3 (5.6) 19 (3.9) 0.476
Heart failure 0 (0.0) 2 (0.4) 1.000
Liver failure 3 (5.6) 8 (1.7) 0.088
Ward type before ICU admission (%)
Operating room 18 (33.3) 260 (53.7) 0.008
Cardiac surgery 10 (18.5) 127 (26.2)
Thoracic surgery 2 (3.7) 42 (8.7)
Neurosurgery 0 (0.0) 31 (6.4)
Other major surgery 6 (11.1) 60 (12.4)
General ward 21 (38.9) 109 (22.5)
Emergency department 15 (27.8) 115 (23.8)
Sepsis at ICU
admission (%)




1.54 (1.04–3.10) 0.86 (0.67–1.19) <0.001
Time to oliguric AKI
(hours; median (IQR))
10.7 (7.4–28.5) 19.0 (10.7–35.5) 0.001
APACHE II score
(median (IQR))
22 (17–27) 17 (13–21) <0.001
SOFA score
(median (IQR))
11 (8–13) 7 (4–9) <0.001
Respiratory 2 (1–3) 2 (1, 2) 0.182
Coagulation 2 (0–2) 1 (0–2) 0.009
Liver 1 (0–1) 0 (0–1) 0.098
Cardiovascular 4 (1–4) 3 (1–4) 0.040
Central nervous system 0 (0–1) 0 (0–1) 0.130
Renal 3 (1–3) 0 (0–1) <0.001
Vasoactive use within 6 h after oliguric AKI diagnosis
Dopamine (%) 0 (0.0) 10 (2.1) 0.609
Dobutamine (%) 9 (16.7) 97 (20.0) 0.718
Norepinephrine (%) 36 (66.7) 205 (42.4) 0.001
Vasopressin (%) 6 (11.1) 14 (2.9) 0.010
Table 2 Patient characteristics, vasoactive use and fluid balance
in ICU patients with oliguric AKI (Continued)
Fluid balance during the first measurable 8-h period after oliguria starting
In (mL; median (IQR)) 949 (691–1526) 758 (530–1096) 0.004
Out (mL; median (IQR)) 272 (158–413) 326 (200–506) 0.028
Balance (mL; median (IQR)) 723 (386–1278) 432 (179–759) <0.001
Time to oliguric acute kidney injury (AKI), time between ICU admission and
oliguric AKI diagnosis. Sequential Organ Failure Assessment (SOFA) scores were
calculated using information during the first 24-h period after ICU admission.
APACHE Acute Physiology and Chronic Health Evaluation, IQR interquartile range
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group) and 80–85 mm Hg (high-target group) in pa-
tients with septic shock (the SEPSISPAM study) did not
support the maintenance of blood pressure much higher
than 65 mm Hg [21]. However, it should be noted that
MAP in most patients in the low-target group in this
trial was actually maintained at higher than 70 mm Hg
[21]. In addition, the target MAP of 80–85 mm Hg in
the high-target group might have been much higher than
necessary. Therefore, some caution would be needed to
interpret the trial results.
Another important result of our study was the associ-
ation between early-phase cumulative hypotension time
and stage-3 progression among oliguric patients with
AKI without sepsis, and the association was weak among
patients with sepsis in any threshold MAP. In this study,
more than 60% of patients without sepsis were postoper-
ative. The mechanism of progression to severe AKI
might be different between patients with sepsis and post-
operative patients with AKI. Postoperative AKI might be
more sensitive to the continuation of hypotension than
septic AKI. Factors other than hypotension might affect
the stage progression in septic AKI.
Is there a “golden time” to treat early-phase AKI, as
in acute myocardial infarction and acute ischemic
stroke? We identified an association between cumula-
tive hypotension time and severe oliguric AKI, even in
a short time-frame such as 6 h after oliguric AKI diagno-
sis. A recent study revealed that urine output responsive-
ness after a furosemide stress test is superior to any recent
biomarker in the prediction of severe-stage progression
Table 3 Blood pressure parameters within 6 h after oliguric AKI diagnosis














(n = 54) (n = 484) (n = 27) (n = 111) (n = 27) (n = 373)
Time-averaged MAP
(mm Hg (IQR))
71 (65–77) 75 (70–83) 0.003 73 (70–81) 75 (71–83) 0.356 70 (62–74) 75 (69–83) 0.001
Lowest MAP
(mm Hg (IQR))
61 (55–67) 65 (60–73) 0.002 62 (59–68) 65 (59–72) 0.301 59 (53–66) 65 (60–73) 0.001
Area under threshold MAP (hours ×mm Hg (IQR))
65 mm Hg 2.0 (0.0–10.2) 0.0 (0.0–3.5) 0.001 1.0 (0.0–6.8) 0.0 (0.0–3.4) 0.159 4.0 (0.0–24.1) 0.0 (0.0–3.5) 0.001
70 mm Hg 10.0 (1.6–29.8) 3.3 (0.0–14.5) 0.001 7.5 (0.8–18.4) 3.3 (0.0–12.4) 0.219 15.5 (4.3–50.8) 3.5 (0.0–15.5) 0.001
75 mm Hg 27.8 (10.9–57.4) 14.4 (0.9–37.0) 0.001 25.5 (5.6–40.0) 15.0 (1.5–33.8) 0.221 39.5 (19.4–78.6) 14.1 (0.8–37.7) <0.001
Time below threshold MAP (hours (IQR))
65 mm Hg 0.5 (0.0–3.2) 0.0 (0.0–1.0) 0.002 0.3 (0.0–1.4) 0.0 (0.0–0.9) 0.157 0.8 (0.0–4.0) 0.0 (0.0–1.0) 0.003
70 mm Hg 2.4 (0.8–4.8) 1.0 (0.0–3.0) 0.002 1.8 (0.4–3.3) 1.0 (0.0–2.8) 0.271 2.8 (1.5–5.8) 0.8 (0.0–3.3) 0.001
75 mm Hg 4.6 (2.1–5.7) 2.8 (0.5–5.0) 0.002 3.5 (1.5–5.4) 2.8 (0.5–4.8) 0.263 5.5 (3.4–5.9) 2.8 (0.5–5.2) 0.001
AKI acute kidney injury; IQR interquartile range, MAP mean arterial pressure
Fig. 2 Graphical representation of the relationship between stage-3 progression and cumulative hypotension time below each threshold mean
arterial pressure (65, 70, and 75 mm Hg) within 6 h after oliguric acute kidney injury (AKI) diagnosis, using restricted cubic splines in univariable
logistic regression models
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[22]. Another study indicated that oliguric AKI is associ-
ated with poor prognosis, even when the serum creatinine
level is not increased [23]. These findings, including ours,
suggest that urine output might be efficient as a continu-
ous monitor. Early diagnosis of oliguric AKI through con-
tinuous urine output monitoring would enable us to
initiate earlier treatment of AKI. Effective treatments have
still not been established for AKI, but future studies might
provide effective procedures including optimal blood pres-
sure levels in patients with early oliguric AKI. If there is a
“golden-time” to treat AKI, early diagnosis by urine output
and early treatment with blood pressure management
would be clinically important.
This study has several limitations. First, the control of
confounding factors may be insufficient because of the
observational study design. It was difficult to obtain data
Table 4 Odds ratios of stage-3 progression in time categories below each threshold MAP













Stage-3 progression 54/538 (10.0) – – 27/138 (19.6) – – 27/400 (6.8) – –
Time spent < MAP 65 mm Hg
None (0 h) 17/266 (6.4) 1.00 Reference 9/65 (13.8) 1.00 Reference 8/201 (4.0) 1.00 Reference
0–3 h 23/216 (10.6) 1.47 (0.71–3.06) 14/60 (23.3) 1.57 (0.60–4.13) 9/156 (5.8) 1.59 (0.52–4.90)
3–6 h 14/56 (25.0) 3.73 (1.53–9.09) 4/13 (30.8) 2.60 (0.61–11.00) 10/43 (23.3) 4.53 (1.35–15.30)
Time spent < MAP 70 mm Hg
None (0 h) 9/167 (5.4) 1.00 Reference 6/40 (15.0) 1.00 Reference 3/127 (2.4) 1.00 Reference
0–3 h 25/228 (11.0) 1.51 (0.64–3.60) 14/67 (20.9) 1.10 (0.37–3.33) 11/161 (6.8) 3.04 (0.70–13.20)
3–6 h 20/143 (14.0) 2.35 (0.96–5.78) 7/31 (22.6) 1.45 (0.41–5.13) 13/112 (11.6) 4.42 (1.03–19.00)
Time spent < MAP 75 mm Hg
None (0 h) 6/109 (5.5) 1.00 Reference 3/23 (13.0) 1.00 Reference 3/86 (3.5) 1.00 Reference
0–3 h 14/165 (8.5) 1.53 (0.52–4.48) 10/47 (21.3) 1.86 (0.44–7.99) 4/118 (3.4) 1.13 (0.21–6.12)
3–6 h 34/264 (12.9) 1.92 (0.72–5.15) 14/68 (20.6) 1.42 (0.35–5.88) 20/196 (10.2) 2.78 (0.66–11.60)
aAdjusted by Acute Physiology and Chronic Health Evaluation (APACHE) II sores, serum creatinine levels at ICU admission, and prevalence of sepsis. bAdjusted by
APACHE II scores, and serum creatinine levels at ICU admission. AKI acute kidney injury, CI confidence interval, MAP mean arterial pressure, OR odds ratio, RRT
renal replacement therapy.
Table 5 Odds ratios for RRT initiation in time categories spent below each threshold MAP













RRT initiation 40/538 (7.4) – – 24/138 (17.4) – – 16/400 (4.0) – –
Time spent < MAP 65 mm Hg
None (0 h) 12/266 (4.5) 1.00 Reference 7/65 (10.8) 1.00 Reference 5/201 (2.5) 1.00 Reference
0–3 h 19/216 (8.8) 1.70 (0.76–3.81) 13/60 (21.7) 1.86 (0.65–5.35) 6/156 (3.8) 1.52 (0.44–5.29)
3–6 h 9/56 (16.1) 3.00 (1.07–8.45) 4/13 (30.8) 3.57 (0.79–16.20) 5/43 (11.6) 2.45 (0.56–10.80)
Time spent < MAP 70 mm Hg
None (0 h) 7/167 (4.2) 1.00 Reference 4/40 (10.0) 1.00 Reference 3/127 (2.4) 1.00 Reference
0–3 h 19/228 (8.3) 1.42 (0.54–3.69) 13/67 (19.4) 1.55 (0.44–5.50) 6/161 (3.7) 1.28 (0.30–5.47)
3–6 h 14/143 (9.8) 2.05 (0.75–5.64) 7/31 (22.6) 2.34 (0.57–9.53) 7/112 (6.2) 1.73 (0.40–7.41)
Time spent < MAP 75 mm Hg
None (0 h) 4/109 (3.7) 1.00 Reference 1/23 (4.3) 1.00 Reference 3/86 (3.5) 1.00 Reference
0–3 h 13/165 (7.9) 2.10 (0.62–7.11) 10/47 (21.3) 7.13 (0.78–65.60) 3/118 (2.5) 0.72 (0.14–3.75)
3–6 h 23/264 (8.7) 1.77 (0.55–5.68) 13/68 (19.1) 4.61 (0.52–41.20) 10/196 (5.1) 0.96 (0.24–3.88)
aAdjusted by Acute Physiology and Chronic Health Evaluation (APACHE) II sores, serum creatinine levels at ICU admission, and prevalence of sepsis. bAdjusted by
APACHE II scores, and serum creatinine levels at ICU admission. AKI acute kidney injury, CI confidence interval, MAP mean arterial pressure, OR odds ratio, RRT renal
replacement therapy.
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on diabetes mellitus, chronic hypertension, the presence
of hypotension before ICU admission, and the exposure
to radiocontrast or nephrotoxic agents. Positive fluid
balance has recently been a well-known risk factor for
patients’ prognoses [24–26]. In our study, only fluid bal-
ance during the first measurable 8-h period after start of
oliguria was available. In addition, more than 50% of the
included patients were postoperative, but it was difficult
to assess retrospectively whether oliguria was due to
hypovolemia. Therefore, the results of this study do not
directly imply that increasing blood pressure itself has
an impact on AKI incidence and progression.
Second, we used only urine output to define AKI and
the AKI stages. Therefore, our definition of AKI did not
strictly follow the definition in the KDIGO criteria.
However, it is well-known that preadmission baseline
creatinine data are often unavailable in clinical practice
[27]. As shown in our previous paper [19], baseline
serum creatinine levels were not known among more
than 50% of the patients in the ICU despite an effort to
obtain the data. In many AKI studies, the serum creatin-
ine back-estimation method has frequently been used
for complementing missing data on baseline serum cre-
atinine [28–30]. However, Bernardi and colleagues have
pointed out that this frequently used method, assuming
a “true” glomerular filtration rate of 75 mL/min/1.73 m2,
is not accurate and that it might have caused misclassifica-
tion [31]. Therefore, although our current study funda-
mentally targeted only urine output as a continuous
monitor, it could be acceptable that we did not use base-
line serum creatinine data.
Third, baseline blood pressure measurements could
not be obtained in this study. Even in the SEPSISPAM
study, which showed no difference in outcomes between
the high-target MAP group and the low-target MAP
group, the proportion of AKI and RRT among patients
with chronic hypertension was lower in the high-target
group than in the low-target group [21]. Consequently,
baseline blood pressure might be an important co-morbid
factor in AKI-related studies.
Last, this study was conducted in a single center, and
the number of patients was small. Although sepsis has
been reported as the leading cause of AKI in the ICU
[1], most patients included in this study were patients
without sepsis rather than patients with sepsis, who
accounted for only 25.7% of the study sample. Therefore,
the generalizability of the study might be limited.
Conclusions
In conclusion, early-phase cumulative hypotension time
below a particular threshold MAP was significantly associ-
ated with progression to the severe stage among critically
ill patients with early oliguric AKI, especially in patients
without sepsis. This association was weak in patients with
sepsis. More attention should be paid to the length of time
spent in hypotension in ICU care.
Key messages
 Early-phase cumulative hypotension time below
threshold MAP was associated with stage-3 progres-
sion of oliguric AKI, especially in patients without
sepsis
 The association was weak and was not significant in
patients with sepsis
 In future AKI research, it is necessary to further
investigate the significance of hypotension duration
and the optimal blood pressure threshold
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